

Name of the Issue:

Rainbow Children's Medicare Limited

Last Updated on:

10-Aug-23

## 1 Type of Issue (IPO/FPO)

IPO

## 2 Issue Size (Rs. Cr)

\* As per Post Offer Report filed with SEBI

1,580.85

## 3 Grade of issue alongwith name of the rating agency

Name

NA

Grade

NA

## 4 Subscription Level (Number of times):

8.82999

\*The above figure is after technical rejection

Source: Final Post Issue Monitoring Report

## 5 QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges

Particulars	%
(i) allotment in the issue*	7.46%
(ii) at the end of the 1st Quarter immediately after the listing of the issue	32.41%
(iii) at the end of 1st FY (March 31, 2023)	19.82%
(iv) at the end of 2nd FY (March 31, 2024)#	Not Available
(v) at the end of 3rd FY (March 31, 2025)#	Not Available

\* As per the Basis of Allotment

# QIB Holding not disclosed as reporting for relevant fiscal years have not been completed.

Source:

(1) Basis of Allotment

(2) Reported to the stock exchanges;

## 6 Financials of the issuer (as per the annual financial results submitted to stock exchanges)

(Rs. Crore)

Parameters (Consolidated)	1st FY (March 31, 2023)	2nd FY (March 31, 2024) <sup>(1)</sup>	3rd FY (March 31, 2025) <sup>(1)</sup>
Income from operations	1,173.57	Not Available	Not Available
Net Profit for the period	212.38	Not Available	Not Available
Paid-up equity share capital	101.50	Not Available	Not Available
Reserves excluding revaluation reserves	958.4	Not Available	Not Available

<sup>(1)</sup> Financials not disclosed as reporting for the fiscal year has not been completed/ not publicly available

## 7 Trading Status in the scrip of the issuer

Company's Equity Shares are listed on both, the BSE Limited and the National Stock Exchange of India Limited.

The Shares have not been suspended or delisted.

Particulars	Status
(i) at the end of 1st FY (March 31, 2023)	NSE - Frequently trade; BSE - Infrequently traded
(ii) at the end of 2nd FY (March 31, 2024)*	Not Applicable
(iii) at the end of 3rd FY (March 31, 2025)*	Not Applicable

\* Trading status not disclosed as the relevant fiscal year has not been completed.

**8 Change in Directors of issuer from the disclosures in the offer document**

Particulars	Name of the Director	Appointed / Resigned
(i) at the end of 1st FY (March 31, 2023)	N.A.	N.A.
(ii) at the end of 2nd FY (March 31, 2024)*	Not Available	Not Available
(iii) at the end of 3rd FY (March 31, 2025)*	Not Available	Not Available

As per the website of BSE and NSE

\* Changes in Directors not disclosed as the relevant fiscal year has not been completed.

**9 Status of implementation of project/ commencement of commercial production**

- (i) as disclosed in the offer document - N.A.
- (ii) Actual implementation - N.A.
- (iii) Reasons for delay in implementation, if any - N.A.

**10 Status of utilization of issue proceeds**

(i) as disclosed in the offer document

Expenditure Item	Rs. Mn
Early redemption of NCDs issued by our Company to CDC Emerging Markets Limited ("CDCEML"), one of our Group Companies, in full	400.00
Capital expenditure towards setting up of new hospitals and purchase of medical	1,700.00
General corporate purposes	561.40

Source: Prospectus

(ii) Actual utilization

Expenditure Item	Rs. Mn
Early redemption of NCDs issued by our Company to CDC Emerging Markets Limited	400.00
Capital expenditure towards setting up of new hospitals and purchase of medical	553.10
General corporate purposes	508.30

(iii) Reasons for deviation, if any - N.A.

**11 Comments of monitoring agency, if applicable**

None

**12 Pricing Data**

Issue Price (Rs.):	542
Designated Stock Exchange:	NSE
Listing Date:	5/10/2022

Price parameters	At close of listing day (May 10, 2022)	At close of 30th calendar day from listing day (June 08, 2022)(1)	At close of 90th calendar day from listing day (August 06, 2022)(2)(3)	As at the end of 1st FY after the listing of the issue (March 31, 2023)			As at the end of 2nd FY after the listing of the issue (March 31, 2024) <sup>(4)</sup>			As at the end of 3rd FY after the listing of the issue (March 31, 2025) <sup>(4)</sup>		
				Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
Market Price (on NSE)	450.2	467.0	472.6	730.5	886.5	410.0	N.A	N.A	N.A	N.A	N.A	N.A
Nifty 50	16,240.1	16,356.3	17,397.5	17,359.8	18,887.6	15,183.4	N.A	N.A	N.A	N.A	N.A	N.A
Sectoral Index	7,779.3	7,651.3	8,135.7	7,621.6	8,719.2	7,249.7	N.A	N.A	N.A	N.A	N.A	N.A

Source: NSE Website

(1) 30th calendar day has been taken as listing date plus 29 calendar days, except where 30th,calendar day is a holiday, in which case we have considered the closing data of the previous trading day

(2) 90th calendar day has been taken as listing date plus 89 calendar days, except where 30th,calendar day is a holiday, in which case we have considered the closing data of the previous trading day

(3) High and Low based on intra day prices

(4) Pricing data not disclosed as the relevant fiscal year has not completed.

## 13 Basis for Issue Price

Accounting ratio	As disclosed in the offer document dated May 02, 2022	At the end of 1st FY (March 31, 2023)#	At the end of 2nd FY (March 31, 2024)#	At the end of 3rd FY (March 31, 2025)#	
EPS	<b>Issuer<sup>(1)</sup>:</b>				
	<b>Consolidated (Basic)</b>	4.36	20.9	Not Available	
	<b>Consolidated (Diluted)</b>	4.25	20.9	Not Available	
	<b>Peer Group:</b>				
	Apollo Hospitals Enterprise Limited	10.74	58.7	Not Available	
	Fortis Healthcare Limited	(1.45)	8.4	Not Available	
	Narayana Hrudalaya Limited	(0.70)	29.7	Not Available	
	Max Healthcare Institute Limited	(1.59)	11.4	Not Available	
	Krishna Institute of Medical Sciences Limited	26.42	45.7	Not Available	
	<b>Industry Avg:</b>	<b>6.684</b>	<b>30.78</b>	<b>Not Applicable</b>	<b>Not Applicable</b>
P/E	<b>Issuer<sup>(1)</sup>:</b>				
	<b>Consolidated (Basic)</b>	124.31	34.9	Not Available	
	<b>Consolidated (Diluted)</b>	127.53	34.9	Not Available	
	<b>Peer Group:</b>				
	Apollo Hospitals Enterprise Limited	428.88	73.4	Not Available	
	Fortis Healthcare Limited	N.A. since EPS is negative	31.0	Not Available	
	Narayana Hrudalaya Limited	N.A. since EPS is negative	26.1	Not Available	
	Max Healthcare Institute Limited	N.A. since EPS is negative	38.8	Not Available	
	Krishna Institute of Medical Sciences Limited	54.19	30.7	Not Available	
	<b>Industry Avg:</b>	<b>241.535</b>	<b>40.0</b>	<b>N.A.</b>	<b>N.A.</b>
RoNW (%)	<b>Issuer<sup>(1)</sup>:</b>				
	<b>Consolidated</b>	8.88%	19.90%	Not Available	
	<b>Peer Group: (Consolidated)</b>				
	Apollo Hospitals Enterprise Limited	3.30%	12.9%	Not Available	
	Fortis Healthcare Limited	-0.75%	7.8%	Not Available	
	Narayana Hrudalaya Limited	-1.46%	28.4%	Not Available	
	Max Healthcare Institute Limited	-2.47%	14.9%	Not Available	
	Krishna Institute of Medical Sciences Limited	23.74%	21.9%	Not Available	
	<b>Industry Avg:</b>	<b>4.47%</b>	<b>17.20%</b>	<b>N.A.</b>	<b>N.A.</b>
	NAV per share based on last balance sheet	<b>Issuer<sup>(1)</sup>:</b>			
<b>Consolidated</b>		86.07	104.9	Not Available	
<b>Peer Group: (Consolidated)</b>					
Apollo Hospitals Enterprise Limited		320.1	454.2	Not Available	
Fortis Healthcare Limited		81.06	107.3	Not Available	
Narayana Hrudalaya Limited		54.82	104.3	Not Available	
Max Healthcare Institute Limited		58.37	76.3	Not Available	
Krishna Institute of Medical Sciences Limited		111.32	208.6	Not Available	
<b>Industry Avg:</b>		<b>125.13</b>	<b>190.2</b>	<b>N.A.</b>	<b>N.A.</b>

<sup>(1)</sup> Consolidated data considered

# Not available as reporting for the relevant period has not been completed / not available publicly

**Notes:**

(1) Sourced from Prospectus dated May 2, 2022.

(2) Information not provided as the relevant fiscal year has not completed

Key ratios for the Company for the three fiscal years stated above shall be calculated as follows:

(i) Basic Earnings per Share (Rs.) = net profit after tax and adjustments, attributable to equity shareholders / Weighted average no. of equity shares

(ii) Diluted Earnings per Share (Rs.) = net profit after tax and adjustments, attributable to equity shareholders (after adjusting profit impact of dilutive

(iii) Total Income = Revenue from Operations and Other Income

(iv) P/E (Basic/Diluted) - Closing Market Price at the end of relevant fiscal year end on BSE/ Basic/Diluted EPS

(v) Return on Net Worth (%) = Net profit after tax, available for equity shareholders / Net worth at the end of the fiscal year.

(vi) Net Asset Value per Equity Share = Net worth at the end of the fiscal year./ Number of equity shares outstanding as at the end of fiscal year

**14 Any other material information**

<b>Date of disclosure</b>	<b>Announcement</b>
9-Feb-23	Rainbow Children's Medicare Limited (Rainbow/Company) on August 29, 2022 has inaugurated a new 55-beds spoke hospital, located at OMR (Sholinganallur) at Chennai. This is Rainbow's first spoke hospital in Chennai. The hospital is designed to provide comprehensive pediatric and obstetrics services. The Company is already operating a 135- beds hub hospital at Guindy, Chennai, Tamil Nadu
1-Mar-23	Company inaugurated a new 100 beds spoke hospital, located at Financial District, Hyderabad, Telangana
15-Apr-23	Upon recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company in their meeting held today i.e., April 15, 2023, approved appointment of Mr. Sanjeev Sukumaran as the Group Chief Operating Officer (Key Managerial Personnel) with effect from April 15, 2023.
26-Apr-23	Company disclosed copy of credit rating letter received today, from ICRA Limited ('ICRA') assigning credit rating to the Company.
31-May-23	The Board of Directors in their meeting held on May 31, 2023, approved appointment of Mr. Vikas Maheshwari as the Chief Financial Officer (Key Managerial Personnel) of the Company with effect from June 1, 2023.
5-Jul-23	Company received allotment letter from Haryana Sheri Vikas Pradhikaran for the allotment of land parcels located in Sector 44 & Sector 56 of Gurugram, Haryana

Source: BSE / NSE website

**Note:** The Company meets Investors/ Analysts/ Participants from time to time. Please refer to the website of the Stock Exchanges for the intimation of the For further updates and information, please refer to the website of the Stock Exchanges i.e. [www.bseindia.com](http://www.bseindia.com) and / or [www.nseindia.com](http://www.nseindia.com).